The global radiotherapy market reached USD 7.63 billion in 2025 and is projected to grow to USD 14.06 billion by 2035, advancing at a compound annual growth rate of 6.3%. This expansion reflects fundamental shifts in cancer care delivery rather than temporary demand fluctuations. Rising cancer incidence, aging demographics, and expanded healthcare spending create sustained demand for radiotherapy across patient populations.
What is driving growth
Technological advancement serves as the primary expansion engine for radiotherapy markets globally. IMRT, SBRT, and MRI-guided LINACs now enable dose concentration on tumors with minimal exposure to healthy tissue, expanding clinical applications and improving patient outcomes. The shift from 2D conventional imaging to real-time image-guided and 3D conformal systems has enhanced accuracy and broadened radiotherapy deployment across hospitals and specialized cancer centers. Robotic radiosurgery platforms, AI-powered adaptive CT-LINAC systems, and real-time motion tracking now allow dynamic treatment plan adjustment during delivery, accelerating adoption of advanced solutions. Simultaneously, rising cancer incidence from aging populations and improved diagnostics expands the patient base requiring radiotherapy, which addresses over half of all cancer treatment regimens. These dual forces of clinical innovation and growing patient demand create durable market expansion.
Restraints and challenges
Infrastructure and resource limitations in low- and middle-income countries restrict market penetration across large regions. Inadequate healthcare facilities, oncology workforce shortages, and limited capital prevent adoption of proton therapy, MRI-guided radiotherapy, and adaptive systems in emerging healthcare networks. Raw material price volatility and logistical disruptions erode producer margins, particularly for smaller regional manufacturers. Tightening environmental and safety standards increase product development timelines and regulatory approval costs. These structural constraints disproportionately affect equipment manufacturers serving under-resourced markets, though compact linear accelerators, AI-assisted planning, and cloud-based workflows gradually improve accessibility.
Radiotherapy addresses over half of all cancer cases worldwide, positioning the modality as central to oncology treatment strategy. Technological innovation, including proton beam therapy, intensity-modulated radiation therapy, MRI-guided systems, adaptive radiotherapy, and AI-enabled treatment planning, has transformed therapeutic precision while reducing collateral tissue damage. By offering, systems dominated with 55.5% market share in 2025, driven by adoption of technology-enabled equipment in developing economies and growing facility infrastructure.
By technology, external beam radiotherapy is projected to register the highest CAGR of 5.7%, reflecting its non-invasive profile and broad applicability across cancer types. EBRT applications commanded 96.0% of market share in 2025, underscoring clinical preference for this modality. Hospitals hold the largest end-user share due to patient volume, equipment availability, and integrated oncology services.
Companies profiled
- Siemens Healthineers AG
- Elekta
- Accuray Incorporated
- IBA Worldwide
- ViewRay Inc
- D capabilities
- Eastern Europe
- LATAM to improve access to oncology treatment
For complete market sizing, forecasts, and competitive intelligence, read the full Radiotherapy Market — covering growth drivers, regional analysis, and leading company profiles through 2033.